GE Vernova stock rises after $1,087 price target — what to watch before earnings
14 January 2026
1 min read

GE Vernova stock rises after $1,087 price target — what to watch before earnings

New York, Jan 13, 2026, 21:30 ET — Market closed

GE Vernova Inc (GEV) shares jumped 1.93% to close at $652.09 Tuesday, following GLJ Research’s boost of its price target to $1,087 from $805 a day earlier.

GLJ analyst Austin Wang maintained his Buy rating but admitted growing caution over the near-term outlook, citing a lack of immediate catalysts and data-center headline risks. The stock edged down roughly 0.3% to $650.20 in late trading. 1

U.S. markets are closed today, shifting focus to GE Vernova’s Q4 and full-year 2025 results set for Jan. 28, released ahead of the opening bell. The company said CEO Scott Strazik and CFO Ken Parks will review the numbers during a 7:30 a.m. ET webcast. 2

The setup matters as GE Vernova finds itself at the heart of a surge to boost generation and reinforce power grids. This trend has attracted both quick-turnaround investors and long-only funds, intensifying the battle over valuation.

GLJ’s long-range numbers keep the debate heating up. The firm projects fiscal 2028 adjusted EBITDA—earnings before interest, taxes, depreciation and amortization—at $13.8 billion, while Wall Street estimates hover near $11 billion, according to a report. 3

The stock has dropped 6.1% in the last month, Zacks Equity Research noted, despite a bounce on Tuesday. Its forward P/E stands around 48, according to Zacks.

Zacks reports that analysts are forecasting GE Vernova to post earnings of $2.99 per share on revenue totaling $10.05 billion in the next earnings release. 4

Yet the bull thesis hits a snag when it comes to supply. Baird’s Ben Kallo cut GE Vernova to Neutral from Outperform this month, citing worries over power-capacity oversupply that are “shifting sentiment.” 5

Baird highlighted competitors and new players like Doosan, while monitoring how fast major turbine manufacturers scale up production. The broker noted GE Vernova aims for around 20 gigawatts of heavy-duty turbine capacity annually by mid-2026, alongside roughly 2 gigawatts of aero units. It also estimated the combined heavy-duty capacity of GE, Siemens, and Mitsubishi Heavy Industries at about 60 gigawatts. 6

GE Vernova separated from General Electric and started trading independently on the New York Stock Exchange in April 2024 under the ticker GEV, the company announced. On its debut, it rang the opening bell together with GE Aerospace. 7

Wednesday’s session will reveal if the raised price target sparks new buying interest or simply satisfies sellers ahead of the next catalyst.

Jan. 28 is the key date here. Investors are zeroed in on orders, margins, and whether management shifts its stance on capacity and competition as 2026 approaches.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Cisco stock rises as FlashStack with Nutanix goes live, with Feb. earnings in focus
Previous Story

Cisco stock rises as FlashStack with Nutanix goes live, with Feb. earnings in focus

Citi to cut 1,000 jobs as BlackRock trims 250 in latest Wall Street layoffs
Next Story

Citi to cut 1,000 jobs as BlackRock trims 250 in latest Wall Street layoffs

Go toTop